Literature DB >> 16190943

Tuberous sclerosis complex and the ketogenic diet.

Eric H Kossoff1, Elizabeth A Thiele, Heidi H Pfeifer, Jane R McGrogan, John M Freeman.   

Abstract

PURPOSE: Tuberous sclerosis complex (TSC) is a condition that is frequently associated with intractable, early-onset epilepsy, and often is first seen as infantile spasms. If medications fail and no clear epileptogenic tuber is identified, nonpharmacologic therapies are often attempted. The use of the ketogenic diet specifically for children with TSC and epilepsy has not been previously described.
METHODS: A chart review was performed of patients with TSC treated with the ketogenic diet over a 5-year period at Johns Hopkins Hospital and Massachusetts General Hospital.
RESULTS: Twelve children, ages 8 months to 18 years, were identified. Eleven (92%) children had a >50% reduction in their seizures at 6 months on the diet, and 8 (67%) had a >90% response. Five children had at least a 5-month seizure-free response. Diet duration ranged from 2 months to 5 years (mean, 2 years).
CONCLUSIONS: In this limited-duration case series of 12 patients, the ketogenic diet was a generally effective therapeutic modality for the intractable epilepsy occasionally seen in children with TSC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16190943     DOI: 10.1111/j.1528-1167.2005.00266.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  32 in total

Review 1.  State of the ketogenic diet(s) in epilepsy.

Authors:  Jennifer Huffman; Eric H Kossoff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

Review 2.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

Authors:  Romina Moavero; Caterina Cerminara; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-04-01       Impact factor: 1.475

Review 3.  Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.

Authors:  Michael Wong
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

4.  Cannabidiol in Patients With Intractable Epilepsy Due to TSC: A Possible Medication But Not a Miracle.

Authors:  Katherine Nickels
Journal:  Epilepsy Curr       Date:  2017 Mar-Apr       Impact factor: 7.500

Review 5.  The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.

Authors:  Paolo Curatolo; Marit Bjørnvold; Patricia E Dill; José Carlos Ferreira; Martha Feucht; Christoph Hertzberg; Anna Jansen; Sergiusz Jóźwiak; J Christopher Kingswood; Katarzyna Kotulska; Alfons Macaya; Romina Moavero; Rima Nabbout; Bernard A Zonnenberg
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 6.  The changing face of dietary therapy for epilepsy.

Authors:  Ludovica Pasca; Valentina De Giorgis; Joyce Ann Macasaet; Claudia Trentani; Anna Tagliabue; Pierangelo Veggiotti
Journal:  Eur J Pediatr       Date:  2016-09-01       Impact factor: 3.183

Review 7.  Hypothalamic hormones and metabolism.

Authors:  Liu Lin Thio
Journal:  Epilepsy Res       Date:  2012-07       Impact factor: 3.045

8.  Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86.

Authors:  Mehmet Canpolat; Huseyin Per; Hakan Gumus; Ali Yikilmaz; Ekrem Unal; Turkan Patiroglu; Levent Cinar; Ali Kurtsoy; Sefer Kumandas
Journal:  Childs Nerv Syst       Date:  2013-06-07       Impact factor: 1.475

Review 9.  Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.

Authors:  Doug Medvetz; Carmen Priolo; Elizabeth P Henske
Journal:  Mol Cancer Res       Date:  2014-10-08       Impact factor: 5.852

Review 10.  Does the effectiveness of the ketogenic diet in different epilepsies yield insights into its mechanisms?

Authors:  Adam L Hartman
Journal:  Epilepsia       Date:  2008-11       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.